Skip to main content
Equibles

4538 · Fuso Pharmaceutical Industries,Ltd. · Financials

Use 4538 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4538.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,201 JPY +24 (+1.10%) At close · Nov 13
Rebalance outlook locked
Market Cap
18.79B JPY
Shares
8.54M
Volume · Nov 13 13.1K Avg daily vol (3M) 20.58K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
62.31B +2.9%
FY2026 Revenue FY2022–FY2026
Net Income
2.01B +161.2%
FY2026 Net Income FY2022–FY2026
Gross Margin
25.67% -1.6pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
4.24% -2.6pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
-6.22B -88.3%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 62.31B 60.56B 55.41B 51.02B 49.63B
JPY 46.31B 44.03B 41.57B 37.28B 36.24B
JPY 16B 16.53B 13.84B 13.74B 13.4B
JPY 2.64B 4.13B 1.96B 2.21B 1.92B
JPY 2.44B -4.97B 1.77B 2.21B 1.91B
JPY 426M -1.68B 389M 599M 427M
JPY 2.01B -3.29B 1.38B 1.61B 1.48B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 3.07B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.